Nabriva Therapeutics (NASDAQ:NBRV) Trading Up 5.6%

Shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) were up 5.6% during mid-day trading on Friday . The company traded as high as $2.43 and last traded at $2.28, approximately 2,692,713 shares traded hands during trading. An increase of 189% from the average daily volume of 933,073 shares. The stock had previously closed at $2.16.

A number of equities research analysts have weighed in on NBRV shares. Northland Securities reaffirmed a “buy” rating and set a $12.50 target price on shares of Nabriva Therapeutics in a research report on Thursday, August 8th. ValuEngine raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price (down from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Nabriva Therapeutics in a research report on Thursday, May 9th. Finally, BidaskClub lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 24th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $7.00.

The company has a current ratio of 5.67, a quick ratio of 5.55 and a debt-to-equity ratio of 0.56. The stock has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $2.39. The firm has a market capitalization of $2.09 billion, a P/E ratio of -1.40 and a beta of 2.40.



Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.04. The business had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.88 million. Nabriva Therapeutics had a negative return on equity of 139.52% and a negative net margin of 3,602.24%. As a group, research analysts expect that Nabriva Therapeutics PLC – will post -1.1 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley raised its position in shares of Nabriva Therapeutics by 52.9% in the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock worth $645,000 after acquiring an additional 91,869 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Nabriva Therapeutics in the 2nd quarter worth $90,000. Parametric Portfolio Associates LLC raised its position in shares of Nabriva Therapeutics by 180.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 33,656 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Nabriva Therapeutics by 51.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after acquiring an additional 443,600 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Nabriva Therapeutics by 92.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after acquiring an additional 155,815 shares in the last quarter. 3.02% of the stock is owned by hedge funds and other institutional investors.

About Nabriva Therapeutics (NASDAQ:NBRV)

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: Green Investing

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.